Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cellular Biomedicine (CBMG)

Cellular Biomedicine (CBMG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 363,397
  • Shares Outstanding, K 19,433
  • Annual Sales, $ 340 K
  • Annual Income, $ -49,980 K
  • 60-Month Beta 1.67
  • Price/Sales 1,061.38
  • Price/Cash Flow N/A
  • Price/Book 11.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.82
  • Growth Rate Est. (year over year) +121,929.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.89 +4.97%
on 09/01/20
18.97 -1.00%
on 08/25/20
+0.04 (+0.21%)
since 08/21/20
3-Month
12.95 +45.02%
on 07/31/20
19.50 -3.69%
on 08/12/20
+5.54 (+41.84%)
since 06/19/20
52-Week
11.48 +63.59%
on 03/16/20
19.50 -3.69%
on 08/12/20
+4.44 (+30.96%)
since 09/20/19

Most Recent Stories

More News
Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Jernigan Capital, Inc. (NYSE: JCAP), and Otelco Inc. (NASDAQ: OTEL)

EQNX::TICKER_START (NASDAQ:OTEL),(NASDAQ:CBMG),(NASDAQ:GLIBA),(NASDAQ:LBRDK),(NYSE:JCAP), EQNX::TICKER_END

LBRDK : 141.61 (+0.57%)
CBMG : 18.78 (+0.43%)
GLIBA : 81.39 (+0.52%)
JCAP : 17.21 (-0.29%)
OTEL : 11.50 (+0.09%)
ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:

RST : 29.94 (+0.23%)
CBMG : 18.78 (+0.43%)
IMMU : 85.50 (-0.04%)
PTI : 1.3100 (+3.15%)
Cellular Biomedi Up 24.4% Since SmarTrend Uptrend Call (CBMG)

SmarTrend identified an Uptrend for Cellular Biomedi (NASDAQ:CBMG) on August 10th, 2020 at $14.82. In approximately 1 month, Cellular Biomedi has returned 24.40% as of today's recent price of $18.43.

CBMG : 18.78 (+0.43%)
INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - RST, CBMG, AIMT, AKCA

Halper Sadeh LLP, a global investor rights law firm, is investigating:

ABCD : 14.48 (unch)
RST : 29.94 (+0.23%)
CBMG : 18.78 (+0.43%)
AIMT : 34.27 (-0.09%)
AKCA : 18.15 (+0.06%)
Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)

, /PRNewswire/ --

MDSY : 0.73 (+4.29%)
CBMG : 18.78 (+0.43%)
GLIBA : 81.39 (+0.52%)
JCAP : 17.21 (-0.29%)
ADI : 112.85 (-1.79%)
NGHC : 33.95 (-0.06%)
OTEL : 11.50 (+0.09%)
PFNX : 12.75 (+0.39%)
SBPH : 1.4000 (-2.10%)
VAR : 172.86 (-0.37%)
MXIM : 65.40 (-1.12%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of PRNB, CBMG, PFNX, and VAR Buyouts

Rigrodsky & Long, P.A. announces that it is investigating:

CBMG : 18.78 (+0.43%)
PRNB : 100.27 (+0.22%)
VAR : 172.86 (-0.37%)
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - RST, CBMG, AIMT, MR

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate:

RST : 29.94 (+0.23%)
CBMG : 18.78 (+0.43%)
AIMT : 34.27 (-0.09%)
MR : 4.52 (+0.89%)
Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc., GCI Liberty, Inc., Jernigan Capital, Inc., and NTN Buzztime, Inc.

EQNX::TICKER_START (NASDAQ:CBMG),(NASDAQ:GLIBA),(NASDAQ:LBRDK),(NYSE:JCAP),(NYSE MKT:NTN), EQNX::TICKER_END

LBRDK : 141.61 (+0.57%)
CBMG : 18.78 (+0.43%)
GLIBA : 81.39 (+0.52%)
JCAP : 17.21 (-0.29%)
NTN : 2.3000 (+15.58%)
WeissLaw LLP Reminds CBMG and MR Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

CBMG : 18.78 (+0.43%)
Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Delmarva Bancshares, Inc. (DLMV), GCI Liberty, Inc. (NASDAQ: GLIBA), and Maxim Integrated Products (NASDAQ:MXIM)

EQNX::TICKER_START (NASDAQ:CBMG),(NASDAQ:GLIBA),(NASDAQ:MXIM),(Other OTC:DLMV),(NASDAQ:LBRDK),(NASDAQ:ADI), EQNX::TICKER_END

DLMV : 8.5000 (unch)
LBRDK : 141.61 (+0.57%)
CBMG : 18.78 (+0.43%)
GLIBA : 81.39 (+0.52%)
ADI : 112.85 (-1.79%)
MXIM : 65.40 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CBMG with:

Business Summary

Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments...

See More

Key Turning Points

2nd Resistance Point 18.93
1st Resistance Point 18.82
Last Price 18.78
1st Support Level 18.50
2nd Support Level 18.29

See More

52-Week High 19.50
Last Price 18.78
Fibonacci 61.8% 16.44
Fibonacci 50% 15.49
Fibonacci 38.2% 14.54
52-Week Low 11.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar